Variable2 | Gln/Arg/HMB (n=30) | Placebo (n=30) | P3 | P-adjusted 14 |
---|---|---|---|---|
CPK (μg/L) | ||||
Baseline | 89.00 (70.25) | 65.50 (117.0) | 0.610* | 0.563¥ |
End of the study | 370.40 ± 447.40 | 396.73 ± 176.76 | 0.121** | 0.156** |
Changes | 123.0 (295.75) | 336.50 (271.75) | 0.059* | 0.116¥ |
P5 | <0.001* | <0.001* | ||
CPK-MB (IU/L) | ||||
Baseline | 19.45 (5.80) | 18.00 (5.25) | 0.858* | 0.526¥ |
End of the study | 49.00 (39.75) | 83.00 (64.55) | 0.011* | 0.032¥ |
Changes | 28.50 (42.3) | 64.80 (60.32) | 0.008* | 0.036¥ |
P5 | <0.001* | <0.001* | ||
Troponin (ng/mL) | ||||
Baseline | 0.02 (0.03) | 0.02 (0.02) | 0.512* | 0.575¥ |
End of the study | 2.13 (1.89) | 4.34 (1.99) | <0.001* | <0.001¥ |
Changes | 2.10 (1.9) | 4.32 (2.01) | <0.001* | <0.001¥ |
P5 | <0.001* | <0.001* | ||
LVEF (%) | ||||
Baseline | 55.0 (5.0) | 50.0 (5.0) | 0.021* | 0.036¥ |
End of the study | 55.0 (5.0) | 50.0 (6.25) | 0.105* | 0.088¥ |
Changes | 0.0 (0.0) | 0.0 (0.0) | 0.531* | 0.313¥ |
P5 | 0.157* | 0.317* | ||
SOFA score | 2.00 (2.00) | 5.00 (2.00) | <0.001* | <0.001¥ |